CureVac’s Final Trading Day: A Chapter Closes in the mRNA Sector

CureVac NL0015436031

The era of CureVac as an independent, publicly-traded entity has concluded. As of January 6, 2026, the Tübingen-based vaccine developer is now wholly owned by its German rival, BioNTech. This definitive acquisition has triggered the immediate suspension of CureVac's stock on the Nasdaq, bringing a volatile investment journey to its end for shareholders. The process now moves into its final administrative phase.

The completion of the buyout renders BioNTech the sole shareholder of CureVac N.V. The financial markets responded without delay. Trading in CureVac's ordinary shares on the Nasdaq Global Market was halted effective immediately. This action extends to the derivatives market, where the MIAX Options Exchange Group has ceased trading in CureVac options as of today. Any remaining open orders were purged at the close of business on January 5.

This move represents the culmination of a significant consolidation within Germany's mRNA technology landscape. BioNTech had already secured a controlling stake of approximately 81.74% in CureVac in early December 2025. The full integration not only terminates CureVac's status as a listed company but also resolves complex intellectual property disputes. Merging the two technology platforms makes protracted patent litigation redundant. Financial research firms, including Alphavalue, have already discontinued coverage of the stock, citing the absence of any meaningful public float.

Final Steps and Forward Focus

The formal delisting from the Nasdaq exchange is scheduled to take effect on January 16, 2026. Following this, the entity plans to file a Form 15 with the U.S. Securities and Exchange Commission (SEC). This filing will terminate the registration of its securities and suspend all ongoing reporting obligations.

Operationally, CureVac's business will continue under the BioNTech umbrella as "CureVac Merger B.V." For former equity holders, the investment thesis is now complete. Market attention has now shifted entirely to BioNTech's upcoming quarterly reports, which will be scrutinized for evidence of how effectively the company integrates CureVac's research pipeline and operational infrastructure.